MTOR and lymphoma: Thus, we here addressed cellular responses to therapeutic inhibition of Pim kinases and identified a PI3K/Akt‐driven activation of mTOR as a significant escape mechanism mitigating the anti‐lymphoma effects of Pim inhibition.